Select Language

HLA-A*0201 & B2M & HPV (TIHDIILECV)

HLA-A*0201 & B2M & HPV (TIHDIILECV) Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag & Avi Tag (1)
Conjugate
Biotin-labeled (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
HLV-H82E5	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&HPV (TIHDIILECV) Complex Protein (Monomer, MALS verified)

Total: 1

HLA-A*0201 & B2M & HPV (TIHDIILECV) Background

Human papillomavirus (HPV) is A kind of papillomavirus belonging to the milk polypoid virus family. It is a spherical D virus, which can cause the proliferation of squamous epithelium of human skin mucosa. HPV(human papillomavirus) for common warts, genital warts (condyloma acuminatum), and other symptoms. There are many types of human papillomavirus (HPV), with HPV 16 and 18 being high-risk types known to significantly increase the risk of cervical, vaginal and vulvar cancers in women and men. The Biotin human HLA-A*0201 HPV (TIHDIILECV) protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and TIHDIILECV peptide of the HPV.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Ningetinib Tosylate	CT-053-PTSA; CT-053	Phase 2 Clinical	Hec Pharm Co Ltd	Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	Details
Do-2	Do-2	Phase 1 Clinical	DeuterOncology NV	Lung Neoplasms	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indication	Clinical Trial
Crizotinib	PF-1066; PF-2341066; PF-02341066; PF-002341066	Approved	Pfizer Inc	赛可瑞, Xalkori	United States	Carcinoma, Non-Small-Cell Lung	Pf Prism Cv	2011-08-26	Urethral Neoplasms; Neoplasm Metastasis; Adenocarcinoma; Neurilemmoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Granuloma, Plasma Cell; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Ureteral Neoplasms; Solid tumours; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Neuroblastoma; Urinary Bladder Neoplasms; Myofibroma; Uveal melanoma; Multiple Myeloma; Neurofibromatosis 2; Neoplasms; Renal Insufficiency; Hematologic Neoplasms	Details